Mircera EPO Will Benefit From Lower Admin Costs Of Monthly Dosing – Roche

Monthly dosing for Roche's continuous erythropoietin receptor activator Mircera may make it attractive to providers because of the lower costs of administration associated with the extended dosing regimens, according to Pharmaceutical Division CEO William Burns